Primary Sector
The NZX discount: Are local investors missing value?
The local bourse has already lost four this year.
Markets
The NZ drug maker facing up to Trump's tariffs
Douglas Pharmaceuticals is raising cash to get a new drug approved. Where will it be made?
Primary Sector
$400m in, $307m out: Synlait finally sheds Pōkeno
From almost collapse to closing in on no debt, deal closes book on Pōkeno.
